Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TScan Therapeutics (TCRX) FCF Margin (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed FCF Margin for 6 consecutive years, with 1244.92% as the latest value for Q4 2025.

  • On a quarterly basis, FCF Margin rose 338020.0% to 1244.92% in Q4 2025 year-over-year; TTM through Dec 2025 was 1310.66%, a 276061.0% increase, with the full-year FY2025 number at 1310.66%, up 276061.0% from a year prior.
  • FCF Margin was 1244.92% for Q4 2025 at TScan Therapeutics, down from 1182.99% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 229.79% in Q3 2023 to a low of 5295.41% in Q1 2024.
  • A 5-year average of 1426.68% and a median of 709.33% in 2022 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: plummeted -488832bps in 2024, then skyrocketed 389168bps in 2025.
  • TScan Therapeutics' FCF Margin stood at 581.32% in 2021, then increased by 12bps to 513.15% in 2022, then increased by 28bps to 368.45% in 2023, then tumbled by -1155bps to 4625.11% in 2024, then skyrocketed by 73bps to 1244.92% in 2025.
  • Per Business Quant, the three most recent readings for TCRX's FCF Margin are 1244.92% (Q4 2025), 1182.99% (Q3 2025), and 1161.87% (Q2 2025).